What are the cardiac manifestations of liver failure?

Cardiac Manifestations of Liver Failure

Liver failure causes a spectrum of cardiac abnormalities including cirrhotic cardiomyopathy (characterized by diastolic dysfunction, blunted systolic response to stress, and QTc prolongation), hyperdynamic circulation with increased cardiac output, and pulmonary vascular complications (hepatopulmonary syndrome and portopulmonary hypertension). 1

Cirrhotic Cardiomyopathy (CCM)

CCM is the primary cardiac manifestation, defined by impaired contractile response to stress and altered diastolic relaxation with electrophysiological abnormalities, occurring without other cardiac disease. 1 This condition is clinically latent at rest but becomes apparent under physiological or pharmacological stress.

Key Features:

• Systolic dysfunction: Resting left ventricular ejection fraction (LVEF) typically remains normal or even elevated (>55%) due to reduced afterload, but there is a blunted contractile response during stress testing 1, 2
• Diastolic dysfunction: The most common finding, present in approximately 57% of patients, diagnosed using average E/e' >14, tricuspid velocity >2.8 m/s, and left atrial volume index >34 ml/m² 1, 3
• QTc prolongation: Occurs in approximately 56% of patients and correlates with disease severity; agents that prolong QT interval should be used cautiously 1, 3
• Cardiac chamber dilation: Increased biventricular volumes despite preserved or increased ejection fraction 2

Pathophysiology:

Systemic inflammation induces myocardial dysfunction through multiple mechanisms including impaired β-adrenergic signaling, altered membrane fluidity, and increased production of cardio-depressant substances (nitric oxide, carbon monoxide, endocannabinoids). Shear stress from portal hypertension may also contribute to myocardial fiber dysfunction. 1

Hyperdynamic Circulation

Patients demonstrate increased cardiac output, decreased systemic vascular resistance, and low arterial blood pressure—a vasodilatory state that worsens with advancing disease and inflammation, particularly in acute-on-chronic liver failure. 4 This hyperdynamic state paradoxically masks underlying cardiac dysfunction at rest.

Pulmonary Vascular Complications

Hepatopulmonary Syndrome (HPS):

• Definition: Pulmonary oxygenation disorder with PaO₂ <80 mmHg or alveolar-arterial gradient ≥15 mmHg (≥20 mmHg if >65 years), plus positive contrast-enhanced echocardiography showing intrapulmonary vascular dilatation 1
• Prevalence: 15-23% in cirrhosis patients, 28% in Budd-Chiari syndrome 1
• Screening: Pulse oximetry <97% on room air warrants further evaluation with contrast-enhanced echocardiography 5

Portopulmonary Hypertension (PPHT):

• Definition: Mean pulmonary artery pressure (mPAP) elevation due to vasoconstriction in portal hypertension 1
• Prevalence: 3-10% based on hemodynamic criteria; female sex and autoimmune liver disease are independent risk factors 1
• Screening: Transthoracic echocardiography in all patients being evaluated for TIPS or liver transplantation; positive screens require right heart catheterization 1
• Transplant contraindication: mPAP ≥45-50 mmHg is an absolute contraindication; mPAP >35 mmHg increases perioperative risk 1

Clinical Implications and High-Risk Scenarios

CCM becomes clinically significant during stressful procedures and is unmasked by:

• Large-volume paracentesis without adequate albumin replacement
• TIPS insertion
• Liver transplantation (cardiac failure is an important cause of post-transplant mortality)
• Major surgery
• Sepsis and acute-on-chronic liver failure 1, 6

Reduced cardiac output in advanced cirrhosis predicts development of acute kidney injury and hepatorenal syndrome, particularly after infections like spontaneous bacterial peritonitis. 1

Diagnostic Approach

Mandatory Baseline Assessment:

1. 12-lead ECG: Evaluate for QTc prolongation (measure corrected QT interval) 1, 7
2. Transthoracic echocardiography: Assess systolic function (LVEF), diastolic parameters (E/e' ratio, tricuspid velocity, left atrial volume), and screen for pulmonary hypertension 7
3. For high-risk patients (age >50, multiple cardiovascular risk factors, pre-transplant evaluation): Cardiopulmonary exercise testing or pharmacological stress testing 7

Advanced Imaging:

• Speckle-tracking echocardiography or cardiac MRI with feature tracking: May detect subclinical myocardial dysfunction through strain analysis, showing reduced right ventricular global longitudinal strain even when conventional measures appear normal 8, 2
• Cardiac MRI: Demonstrates increased extracellular volume fraction correlating with disease severity (Child-Pugh class and MELD score), indicating myocardial fibrosis 2

Management Considerations

No specific treatment exists for CCM; manage cardiac complications as in non-cirrhotic patients with sodium restriction, diuretics, and oxygen when necessary. 6 However, exercise extreme caution with:

• ACE inhibitors and angiotensin antagonists: Use with caution due to risk of worsening hypotension in the vasodilatory state 6
• Beta-blockers in PPHT: Should be discontinued; manage varices with endoscopic therapy instead 1
• TIPS: Contraindicated in patients with PPHT 1

Pre-Transplant Optimization:

Detailed functional cardiac characterization is mandatory before TIPS or liver transplantation. Improved liver function post-transplant can reverse cardiac abnormalities, but perioperative cardiac failure remains a significant mortality risk. 7, 6

Monitoring Disease Progression:

The correlation between cardiac dysfunction severity and liver disease severity (Child-Pugh score, MELD score) necessitates serial cardiac assessment as liver disease progresses. 3, 2